After intranasal NAP treatment in the mouse models above (and below), as well as in an AD mouse model, a decrease in Tau hyperphosphorylation and a beneficial effect on Aβ aggregation in an early state of the disease (9–12 months) were observed [124, 125]. Here, MAPT is linked to Alzheimer disease.